Log in

NASDAQ:NOVN - Novan Stock Price, Forecast & News

$0.46
-0.06 (-11.54 %)
(As of 02/26/2020 01:54 AM ET)
Today's Range
$0.46
Now: $0.46
$0.54
50-Day Range
$0.44
MA: $0.58
$0.76
52-Week Range
$0.41
Now: $0.46
$3.72
Volume409,600 shs
Average Volume893,697 shs
Market Capitalization$12.29 million
P/E RatioN/A
Dividend YieldN/A
Beta2.32
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NOVN
CUSIPN/A
Phone919-485-8080

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.99 million
Book Value$0.20 per share

Profitability

Net Income$-12,670,000.00
Net Margins-348.29%

Miscellaneous

Employees47
Market Cap$12.29 million
Next Earnings Date3/25/2020 (Estimated)
OptionableNot Optionable

Receive NOVN News and Ratings via Email

Sign-up to receive the latest news and ratings for NOVN and its competitors with MarketBeat's FREE daily newsletter.


Novan (NASDAQ:NOVN) Frequently Asked Questions

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) released its earnings results on Friday, May, 12th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.49) by $0.24. The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $10.80 million. View Novan's Earnings History.

When is Novan's next earnings date?

Novan is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Novan.

What price target have analysts set for NOVN?

3 equities research analysts have issued 1-year price objectives for Novan's stock. Their forecasts range from $0.50 to $1.50. On average, they anticipate Novan's share price to reach $1.00 in the next year. This suggests a possible upside of 117.4% from the stock's current price. View Analyst Price Targets for Novan.

What is the consensus analysts' recommendation for Novan?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novan in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novan.

Has Novan been receiving favorable news coverage?

Media coverage about NOVN stock has trended very positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Novan earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Novan.

Are investors shorting Novan?

Novan saw a drop in short interest in January. As of January 31st, there was short interest totalling 188,700 shares, a drop of 77.7% from the January 15th total of 847,400 shares. Based on an average trading volume of 405,000 shares, the days-to-cover ratio is presently 0.5 days. Currently, 1.1% of the shares of the company are sold short. View Novan's Current Options Chain.

Who are some of Novan's key competitors?

What other stocks do shareholders of Novan own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novan investors own include Melinta Therapeutics (MLNT), SCYNEXIS (SCYX), MannKind (MNKD), Trevena (TRVN), Vuzix (VUZI), Valero Energy (VLO), Washington Prime Group (WPG), Biocept (BIOC), Cirrus Logic (CRUS) and Heron Therapeutics (HRTX).

Who are Novan's key executives?

Novan's management team includes the folowing people:
  • Mr. G. Kelly Martin, CEO & Director (Age 60)
  • Ms. Paula Brown Stafford, Pres, COO & Director (Age 54)
  • Mr. John M. Gay, VP of Fin., Corp. Controller, Principal Financial Officer and Corp. Sec. (Age 42)
  • Dr. Nathan Stasko, Co-Founder & Chief Scientific Officer (Age 39)
  • Dr. Carri Geer, Sr. VP & CTO

When did Novan IPO?

(NOVN) raised $46 million in an initial public offering (IPO) on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Novan's major shareholders?

Novan's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Cardinal Capital Management (0.19%) and Vigilant Capital Management LLC (0.11%). Company insiders that own Novan stock include G Kelly Martin, John M Gay, John W Palmour, Life Sciences Holdings L Malin, Paula B Stafford and Robert Alexander Ingram. View Institutional Ownership Trends for Novan.

Which institutional investors are buying Novan stock?

NOVN stock was acquired by a variety of institutional investors in the last quarter, including Cardinal Capital Management and Vigilant Capital Management LLC. Company insiders that have bought Novan stock in the last two years include G Kelly Martin, John M Gay, John W Palmour, Paula B Stafford and Robert Alexander Ingram. View Insider Buying and Selling for Novan.

How do I buy shares of Novan?

Shares of NOVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Novan's stock price today?

One share of NOVN stock can currently be purchased for approximately $0.46.

How big of a company is Novan?

Novan has a market capitalization of $12.29 million and generates $5.99 million in revenue each year. The company earns $-12,670,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Novan employs 47 workers across the globe.View Additional Information About Novan.

What is Novan's official website?

The official website for Novan is http://www.novantherapeutics.com/.

How can I contact Novan?

Novan's mailing address is 4105 HOPSON ROAD, MORRISVILLE NC, 27560. The company can be reached via phone at 919-485-8080 or via email at [email protected]


MarketBeat Community Rating for Novan (NASDAQ NOVN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  263 (Vote Underperform)
Total Votes:  465
MarketBeat's community ratings are surveys of what our community members think about Novan and other stocks. Vote "Outperform" if you believe NOVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel